Aparna Vaidik, My Son's Inheritance: A Secret History of Lynching and Blood Justice in India. New Delhi: Aleph Book Company, 2020, pp. 173, ₹499. ISBN: 978-81-942337-8-7.
The discourse on Kashmiriyat (or Kasheryut) was majorly invoked in the late twentieth-century Kashmir by diverse, often conflicting, ideological strands to legitimize their respective political positioning in the context of post-1947 political stirrings in Jammu and Kashmir. However, the discourse has remained shrouded in ambiguity owing to the multiple, disparate meanings and connotations attached to it. More commonly the term has been understood to imply a syncretic culture of Kashmir devoid of religious fundamentalism and exclusion.KL So far as the historicity of Kashmiriyat is concerned, the existing scholarly writings on the discourse have tried to locate its origins in the medieval times when the interaction and subsequent synthesis occurred between Hinduism and Islam in Kashmir; a mystic manifestation, Rishism, is often referred as the best example of this ideational formation. However, the paper attempts to argue that while the idea of Kashmiriyat as syncretic culture of Kashmir devoid of religious fundamentalism holds ground, it cannot be clearly steered away from a particular religious affiliation altogether. Secondly, this paper challenges the existing historicity and ideational trajectory of Kashmiriyat and instead attempts to trace its genealogy to Kashmir's ancient past.
Travelling in a motor car is a popular mode of conveyance across Pakistan. Similarly, motorists constitute about 66% of total registered cars in Peshawar District which observed a 200% increase from 2006 to 2016. The current research estimates a Random Parameter Logit (RPL) Model by heterogeneousness means & variations in order to identify various parameters that contribute to the motorists' brutality of injury. The effects of motorist traits, temporal characteristics, motor vehicle features, roadway attributes, weather characteristics and effects of speed limits were predominantly considered for this analysis. Generally, typical approximation results show that the chance and severity of injuries increase for accidents including young drivers, winter indicators, and crashes that occurred between 10 AM-02 PM. Likewise, minor wound smashes are more likely to involve senior drivers, occurring during sunny weather, in the autumn season and in the month of August. Safety measures are suggested based on the findings of this research study to improve professional's motorist safety e.g. educating drivers about traffic rules and safety, zero tolerance for driving without a valid license, and enforcing speed limits on the roads. The results of this study will help in formulating strategies to improve motorists' safety.
BACKGROUND: The northern part of the province of Khyber Pakhtunkhwa in Pakistan experienced armed conflict since September 2007 till the autumn of 2011. Conflict involved widespread insurgency activity and military intervention including in 2009 internally displacing the 2.5 million people of the valley of Swat to live in camps, with relatives, or in rented accommodation across the region for approximately 4 months. It was during this period the current study was conducted to determine whether Post-Traumatic Stress Disorder in pregnant women was independently associated with Low Birth Weight (LBW) in an area affected by conflict and militancy. METHODS: A case control study was conducted in tertiary care hospitals of district Peshawar, Khyber Pakhtunkhwa. Two hundred twenty-five cases (neonates with birth weight 2.5 kg) were enrolled within 24 h of delivery. Post-Traumatic Stress Disorder was assessed through the MINI Neuropsychiatric Interview 5.0, a validated questionnaire along with the birth weight of the newborn. Maternal anthropometry, anemia and other sociodemographic details were also obtained during data collection. Data was analyzed using statistical package (STATA version 14). Logistic regression analysis of the association between LBW and all variables collected with a p-value of < 0.25 on uni-variate analysis were entered. RESULTS: A total of 450 newborn and mother pairs participated in the study with 225 cases and 225 controls. On univariate analysis factors significantly associated with LBW include: less than 5 years of paternal schooling and PTSD. On logistic regression, PTSD was independently associated with low birth weight in the presence of other factors like maternal/paternal schooling, gravida, history of preterm, BMI of the mother and maternal anemia. CONCLUSION: PTSD was found to be independently associated with LBW. In light of the current findings and other similar literature, intervention programs should be considered ...
Background and objectives The 52‐week, randomized, double‐blind, noninferiority, government‐funded NOR‐SWITCH trial demonstrated that switching from infliximab originator to less expensive biosimilar CT‐P13 was not inferior to continued treatment with infliximab originator. The NOR‐SWITCH extension trial aimed to assess efficacy, safety and immunogenicity in patients on CT‐P13 throughout the 78‐week study period (maintenance group) versus patients switched to CT‐P13 at week 52 (switch group). The primary outcome was disease worsening during follow‐up based on disease‐specific composite measures. Methods Patients were recruited from 24 Norwegian hospitals, 380 of 438 patients who completed the main study: 197 in the maintenance group and 183 in the switch group. In the full analysis set, 127 (33%) had Crohn's disease, 80 (21%) ulcerative colitis, 67 (18%) spondyloarthritis, 55 (15%) rheumatoid arthritis, 20 (5%) psoriatic arthritis and 31 (8%) chronic plaque psoriasis. Results Baseline characteristics were similar in the two groups at the time of switching (week 52). Disease worsening occurred in 32 (16.8%) patients in the maintenance group vs. 20 (11.6%) in the switch group (per‐protocol set). Adjusted risk difference was 5.9% (95% CI −1.1 to 12.9). Frequency of adverse events, anti‐drug antibodies, changes in generic disease variables and disease‐specific composite measures were comparable between arms. The study was inadequately powered to detect noninferiority within individual diseases. Conclusion The NOR‐SWITCH extension showed no difference in safety and efficacy between patients who maintained CT‐P13 and patients who switched from originator infliximab to CT‐P13, supporting that switching from originator infliximab to CT‐P13 is safe and efficacious.
Background and objectives The 52‐week, randomized, double‐blind, noninferiority, government‐funded NOR‐SWITCH trial demonstrated that switching from infliximab originator to less expensive biosimilar CT‐P13 was not inferior to continued treatment with infliximab originator. The NOR‐SWITCH extension trial aimed to assess efficacy, safety and immunogenicity in patients on CT‐P13 throughout the 78‐week study period (maintenance group) versus patients switched to CT‐P13 at week 52 (switch group). The primary outcome was disease worsening during follow‐up based on disease‐specific composite measures. Methods Patients were recruited from 24 Norwegian hospitals, 380 of 438 patients who completed the main study: 197 in the maintenance group and 183 in the switch group. In the full analysis set, 127 (33%) had Crohn's disease, 80 (21%) ulcerative colitis, 67 (18%) spondyloarthritis, 55 (15%) rheumatoid arthritis, 20 (5%) psoriatic arthritis and 31 (8%) chronic plaque psoriasis. Results Baseline characteristics were similar in the two groups at the time of switching (week 52). Disease worsening occurred in 32 (16.8%) patients in the maintenance group vs. 20 (11.6%) in the switch group (per‐protocol set). Adjusted risk difference was 5.9% (95% CI −1.1 to 12.9). Frequency of adverse events, anti‐drug antibodies, changes in generic disease variables and disease‐specific composite measures were comparable between arms. The study was inadequately powered to detect noninferiority within individual diseases. Conclusion The NOR‐SWITCH extension showed no difference in safety and efficacy between patients who maintained CT‐P13 and patients who switched from originator infliximab to CT‐P13, supporting that switching from originator infliximab to CT‐P13 is safe and efficacious. ; publishedVersion ; Open Access CC-BY